FindTrial
Sign In

Safety and efficacy of remimazolam combined with different opioids in bronchoscopic examination or therapy

Safety and efficacy of remimazolam combined with different opioids in bronchoscopic examination or therapy: a prospective, double-blind, randomized, parallel group trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047768
Enrollment
Unknown
Registered
2021-06-26
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchobiopsic Examination and Therapy

Interventions

Experimental group1:Remimazolam sedation+Sufentanil 0.03~0.1 ug/kg, iv, once
Experimental group2:Remimazolam sedation+alfentanil 0.5~2 ug/kg, iv, once
Experimental group3:Remimazolam sedation+remifentanil 0~0.2 ug/kg, iv, as needed

Sponsors

The Second Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 70 years; 2.Ask for painless bronchobiopsic examination or therapy.

Exclusion criteria

Exclusion criteria: 1. Severe heart disease, severe chronic obstructive pulmonary disease, chronic liver disease, renal failure, morbid obesity (BMI greater than 40kg/m2), severe OSAS; 2. ASA classification 3-4.

Design outcomes

Primary

MeasureTime frame
Complete of the examination or therapy;—

Secondary

MeasureTime frame
Time of the procedure;Time for satisfied sedation;Sedation score;Time to revive after the procedure;—

Countries

China

Contacts

Public ContactDai Ruping

The Second Xiangya Hospital, Central South University

xyeyyrupingdai@csu.edu.cn+86 18974924753

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026